17 April 2026 in iScience
Basal keratinocytes (KCs) exhibit enhanced proliferative activity alongside severely impaired differentiation in psoriasis. Accumulating evidence has implicated dysregulation of the neddylation pathway in various human diseases; however, its role in psoriasis remains largely unexplored. In this study, we assessed global neddylation levels and the expression of neddylation-associated enzymes in both human psoriatic lesions and imiquimod (IMQ)-induced murine models of psoriasis. Our results revealed a significant upregulation of the E2-conjugating enzyme UBE2M in psoriatic lesions. UBE2M promotes psoriatic pathogenesis by enhancing keratinocyte proliferation and inflammatory responses. Both genetic and pharmacological inhibition of UBE2M suppressed psoriasis-like development in vitro and in vivo. Mechanistically, we showed that UBE2M enhances keratinocyte proliferation and migration by increasing neddylation-mediated modification of EGFR, thereby stabilizing and activating EGFR. The results highlight the therapeutic potential of targeting UBE2M and neddylation in psoriasis treatment.